Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Risk of Infective Endocarditis in Patients with End Stage Renal Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Does Changing the Volume Matter? The Relationship of Urine Volume and Dialysis Intensity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sergei I. Petrykiv
  • C David Sjöström
  • Peter J Greasley
  • John Xu
  • Frederik Persson
  • Hiddo J Lambers Heerspink
View graph of relations

BACKGROUND AND OBJECTIVE: Sodium glucose cotransporter 2 inhibition with dapagliflozin decreases hemoglobin A1c (HbA1c), body weight, BP, and albuminuria (urinary albumin-to-creatinine ratio). Dapagliflozin also modestly increases hematocrit, likely related to osmotic diuresis/natriuresis. Prior studies suggest that the HbA1c-lowering effects of dapagliflozin attenuate at lower eGFR. However, effects on other cardiovascular risk factors at different eGFR levels are incompletely understood.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This pooled analysis of 11 phase 3 clinical trials assessed changes in HbA1c, body weight, BP, hematocrit, and urinary albumin-to-creatinine ratio with placebo (n=2178) or dapagliflozin 10 mg (n=2226) over 24 weeks in patients with type 2 diabetes according to baseline eGFR (eGFR≥45 to <60 ml/min per 1.73 m(2), eGFR≥60 to <90 ml/min per 1.73 m(2), and eGFR≥90 ml/min per 1.73 m(2)).

RESULTS: Compared with placebo, reductions in HbA1c with dapagliflozin were 0.6%, 0.5%, and 0.3%, respectively, for each consecutive lower eGFR subgroup (P value interaction <0.001). Effects of dapagliflozin on hematocrit, body weight, and BP were similar regardless of baseline eGFR, suggesting that effects potentially related to volume and natriuresis are eGFR independent. Moreover, among individuals with baseline urinary albumin-to-creatinine ratio ≥30 mg/g, placebo-adjusted reductions in urinary albumin-to-creatinine ratio were larger in the lowest eGFR subgroup (P value interaction <0.001). Adverse events occurred more frequently in the lowest eGFR subgroup; this was true for both dapagliflozin- and placebo-treated patients.

CONCLUSIONS: The HbA1c-lowering effects of dapagliflozin decrease as renal function declines. However, dapagliflozin consistently decreases body weight, BP, and urinary albumin-to-creatinine ratio regardless of eGFR. These effects in conjunction with the finding of similar effects on hematocrit, a proxy for volume contraction, suggest that the effects of dapagliflozin are partly mediated via nonglucosuric-dependent mechanisms.

Original languageEnglish
JournalClinical journal of the American Society of Nephrology : CJASN
Issue number5
Pages (from-to)751-759
Number of pages9
Publication statusPublished - 8 May 2017

    Research areas

  • Journal Article

ID: 51454659